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An outbreak of severe acute respiratory syndrome
(SARS) in humans, associated with a new coronavirus,
was reported in Southeast Asia, Europe, and North
America in early 2003. To address speculations that the
virus originated in domesticated animals, or that domestic
species were susceptible to the virus, we inoculated 6-
week-old pigs and chickens intravenously, intranasally,
ocularly, and orally with 106 PFU of SARS-associated coro-
navirus (SARS-CoV). Clinical signs did not develop in any
animal, nor were gross pathologic changes evident on
postmortem examinations. Attempts at virus isolation were
unsuccessful; however, viral RNA was detected by reverse
transcriptase-polymerase chain reaction in blood of both
species during the first week after inoculation, and in chick-
en organs at 2 weeks after inoculation. Virus-neutralizing
antibodies developed in the pigs. Our results indicate that
these animals do not play a role as amplifying hosts for
SARS-CoV.
A
n outbreak of severe acute respiratory syndrome
(SARS) in humans, associated with a new coron-
avirus (SARS-CoV), has been reported in Southeast Asia,
Europe, and North America (1–3). According to the World
Health Organization, SARS affected more than 8,200 peo-
ple worldwide and killed more than 700. The sequence
analysis of SARS-CoV suggests that it is substantially dis-
tinct from all other known coronaviruses (1,2). Based on
the nucleotide sequence, the virus is speculated to have
evolved and been maintained in an animal host. However,
no conclusive data have been presented to date on a possi-
ble reservoir for this virus. Our study aimed to address the
role of domestic animals in the outbreak, both from the
public health perspective (as a potential source of virus for
human infections) and the animal health perspective. A
potential susceptibility of domestic species to SARS-CoV
would have major implications on the management of live-
stock operations worldwide.
We have experimentally inoculated chickens and
swine. Both species are natural hosts for a number of
viruses from the same family as SARS-CoV
(Coronaviridae). The infectious bronchitis virus of chick-
ens, although distinct, groups genetically most closely
with SARS-CoV (1,2). Swine can host several coron-
aviruses (hemagglutinating encephalomyelitis virus, trans-
missible gastroenteritis virus [TGEV], and porcine respira-
tory coronavirus [PRCV]). In addition, continuous cultures
of porcine turbinate cells (PT-K75) and primary chicken
embryo epithelial kidney cells supported SARS-CoVrepli-
cation.
Material and Methods
Animals
Six 4-week-old crossbred pigs were kept for 2 weeks to
acclimatize before being inoculated. The pigs, obtained
from a high health status herd (Sunnyside Colony LTD,
Sunnyside, Manitoba), had preexisting antibodies against
PRCV, likely of maternal origin (4), which decreased dur-
ing the experiment, as determined by competitive enzyme-
linked immunosorbent assay performed by the Veterinary
Services Branch of Manitoba Agriculture and Food.
Six-week-old, nonvaccinated, specific-pathogen-free
chickens (White Leghorn), obtained from ADRI Nepean
(Nepean, Ontario) were kept for 3 days to acclimatize
before inoculation. They were housed in chicken isolators
inside a biosafety level 4 (BSL4) animal cubicle. Animal
housing and all animal manipulations were approved by
the Animal Care Committee of the Canadian Science
Centre for Human and Animal Health and met the
Canadian Council on Animal Care guidelines.
Virus
SARS-CoV was plaque purified from a human isolate
(Tor 3) on Vero E6 cells by using the plaquing method we
describe in the SARS-CoV antibody detection section.
Virus stock for animal inoculation was prepared and titrat-
ed on Vero V76 cells. Virus replication in Vero E6, Vero
V76, and PT-K75 cells was compared by employing the
following plaque assay: an aliquot of each virus dilution
was added in duplicate onto cell monolayers in 12-well
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Winnipeg, Manitoba, Canadaplates (Costar, Corning, NY). Virus inoculum was then
incubated on cells for 1 h at 37°C, 5% CO2, and removed.
The cells were overlayed with 2% carboxymethyl-cellu-
lose (Sigma, St. Louis, MO)/ Dulbecco modified Eagle
medium (DMEM) (Wisent, St. Bruno, Quebec), and incu-
bated at 37°C, 5% CO2, for 4 days. At the end of the incu-
bation, the cells were fixed with 4% formaldehyde and
stained with crystal violet. The experiment was repeated
twice.
Cells
Vero E6 and Vero V76 (ATCC) cells were maintained
in 10% fetal bovine serum (FBS)/DMEM medium
(Sigma). Porcine turbinate PT-K75 (ATCC) cells were
maintained in 10% FBS/ DMEM (Wisent). Quail QT-35
(ATCC) cells were maintained in 10% FBS/MEM-alpha
medium (Mediatech Cellgro, Herndon, VA).
For the preparation of primary chicken embryo kidney
epithelial cells (CEKEC), kidneys were harvested from 18-
day-old chicken embryos and digested with 3 U of pronase
(Sigma)/mLin citrate buffer (1.5 mM KCl, 27 mM sodium
citrate, 8 mM KH2PO4, 5.6 mM Na2HPO4, pH 7.3) by
repeated incubation for 2 min at 37°C with stirring. Cells
were collected into fetal bovine serum and washed exten-
sively with phosphate-buffered saline before being seeded
into 24-well plates (Costar). Cells were seeded at a densi-
ty of 106 cells/cm2 in 1% FBS/Williams medium (Sigma)
for the virus isolation. The cell suspension contained about
95% epithelial cells and 5% fibroblasts after 24 h of incu-
bation, as previously determined by immunofluorescent
assay; markers for epithelial cells (cytokeratin) and fibrob-
lasts (vimentin) were detected.
Experimental Infection
The preimmune serum from chickens and pigs was col-
lected 2 days before inoculation. Six-week-old pigs were
inoculated simultaneously by four routes, intravenously,
intranasally, ocularly, and orally, with 2 x 106 PFU of
SARS-CoV per pig. Six-week-old chickens were inoculat-
ed by the same routes with 106 PFU of SARS-CoV per
chicken. Three pigs and three chickens were mock inocu-
lated and served as negative controls. Both species were
divided into two groups, and blood, nasal (nares), throat,
and rectal (cloacal) swabs were collected on alternate days,
starting at 2 days after inoculation (dpi) and ending at 7
dpi. On days 6, 7, 13, 14, 15, and 16 after inoculation, one
pig and one chicken per day were euthanized. In addition
to swabs and blood, samples from lung, trachea, liver,
heart, spleen, kidney, tonsil (pig), and jejunum were col-
lected at postmortem examination. All experimental work
was carried out in BSL4 containment.
Virus Isolation
Virus isolation from porcine samples was attempted on
Vero V76 and porcine turbinate cells PT-K75, seeded at a
density of 2 x 105 cells/cm2 in 12-well plates (Costar) 24 h
before inoculation. Samples were tested in duplicate twice,
by plaque assay (described in Virus section) and monitor-
ing cytopathic effect (CPE), followed by reverse transcrip-
tase–polymerase chain reaction (RT-PCR) to detect virus
replication. In addition, virus isolation from chicken sam-
ples was attempted on chicken embryo epithelial kidney
cells, seeded at a density of 106 cells/cm2 in 24-well plates
(Costar), using CPE format followed by RT-PCR.
The tissues were ground in a MiniMix blender (Topac,
Hingham, MA) to prepare a 10% w/v suspension in
Dulbecco’s PBS (Sigma) supplemented with antimicrobial
drugs and stood for 1 h in the antimicrobial mix (strepto-
mycin/vancomycin/nystatin/gentamycin). The suspension
was centrifuged at 2000 x g, 4°C, 20 min. The supernatant
was diluted 10-fold in the corresponding media for the
individual cell types, and 400 µL (in duplicates) was incu-
bated on cells for 1 h at 37°C, 5% CO2. The inoculum was
then removed and replaced with the appropriate media,
supplemented with 5% FBS (Vero and PT-K75 cells) or
1% FBS (CEEKC). Plates were incubated for 5 days at
37°C, 5% CO2. Isolation from blood and swabs was per-
formed as for tissues without the homogenization step. The
sensitivity of virus isolation was determined by spiking
negative control lung tissues from one chicken and one pig
with virus inoculum before homogenization, titrating out
the samples on Vero E6 and Vero V76 cells, and compar-
ing the titers to the inoculum titer, using plaque assay
described in the virus section.
RT-PCR
RNAwas extracted from blood and tissue samples with
the TriPure Extraction kit (Roche Diagnostics,
Indianapolis, IN). Three sets of primers were used in a
one-step RT-PCR assay employing the Qiagen OneStep
RT-PCR kit (Qiagen, Mississauga, ON): 1. NML poly-
merase primers: forward primer CAG AGC CAT GCC
TAACATG and reverse primer AAT GTTTAC GCAGGT
AAG CG were used in the RT-PCR reaction (50°C for 30
min, 95°C for 15 min, followed by 50 cycles of 94°C for
15 s, 50°C for 30 s, 72°C for 30 s with 7-min extension at
72°C). The 389-nt amplicon is located within the RNA-
dependent RNA polymerase gene (ORF 1b). 2.
Nucleocapsid (N) primers: forward primer ATAATA CTG
CGT CTT GGT TC and reverse primer TGG CAA TGT
TGT TCC TTG AG were used under the same reaction
conditions as the first set of primers, yielding a 364-base
pair (bp) long amplicon. 3. BNI polymerase primers and
RT-PCR conditions were developed at the Bernhard-Nocht
Institute for Tropical Medicine, Hamburg, Germany, by
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2003: BNI OUT S2: ATG AAT TAC CAAGTC AAT GGT
TAC (forward); BNI OUTAS: CATAAC CAG TCG GTA
CAG CTA C (reverse). The RT-PCR conditions were: 30
min at 50°C, 15 min at 95°C, followed by 50 cycles of
95°C for 10 s, 56°C for 10 s, 72°C for 20 s, and complet-
ed at 72°C for 7 min, yielding an amplicon of 195 bp.
The Qiagen OneStep RT-PCR kit was also used for the
two-step RT-PCR with the following modifications: the
template was incubated at 50°C for 30 min only with for-
ward N primer followed by the incubation at 95°C for 15
min to inactivate the reverse transcriptase. Residual single-
strand RNA template was removed by digestion at 37°C
for 20 min with 2 U of Rnase H (Invitrogen, Burlington,
ON). After both forward and reverse N primers and the
Platinum Pfx DNA polymerase (Invitrogen) were added,
the DNAsynthesis was completed by using the above con-
ditions for the N primers in a one-step RT-PCR. Randomly
selected amplicons were sequenced with the respective
primers to verify the identity of the bands. Sensitivity of
the individual primer sets used in the RT-PCR assays was
tested by spiking negative control lung tissues from chick-
en and pig with virus inoculum before homogenization,
titrating out the homogenate, and running the RT-PCRs in
parallel on the same RNA extracts.
SARS-CoV Antibody Detection
Porcine serum collected before inoculation and during
the final bleed was tested for antibodies against SARS by
a standard plaque reduction neutralizing test, as previous-
ly described (5). Briefly, mixtures of pre-titered (100
PFUs) SARS-CoV and serial twofold dilutions of animal
sera were incubated at 37°C for 1 h and added to 6-well
plates containing Vero E6 cell monolayers. After a 37°C
incubation for 1 h, a nutrient-agar overlay was added, and
the plates were placed in a CO2 incubator for approximate-
ly 3 days. Asecond overlay, which contained neutral red as
a vital stain, was then added. Plates were then checked
periodically over the next few days for plaque formation.
The highest serum dilution, which produced a plaque
reduction of at least 90%, was defined as the titration end
point.
Porcine Serum Cross-Reactivity with TGEV/PRCV
Serum samples collected on the pre-inoculation bleed
and terminal bleed were tested for neutralizing antibodies
against SARS and TGEV/PRCV by using microtiter CPE
blocking assay. Each of the above viruses was diluted to
100 50% tissue culture infective dose (TCID50)/well,
mixed with doubling serial dilutions of test serum begin-
ning at 1:5 (giving the first serum dilution 1:10), and incu-
bated for 1 h at 37°C. The virus-serum mixtures were then
added to 96-well microtiter plates (Costar) containing
overnight confluent monolayers of Vero V76 cells or PT-
K75 cells, for the SARS or TGEV CPE-blocking assay,
respectively. The results were read after 3 days of incuba-
tion at 37°C, 5% CO2.
Results
Preliminary tests to establish a sensitive cell system for
virus replication were performed before animal inocula-
tion and virus isolation. SARS-CoV replicated in Vero E6,
Vero V76, and PT-K75 approximately to the same titer.
QT-35 did not replicate SARS-CoV. Although CEKEC did
not show any CPE, the virus replicated in those cells up to
the approximate titer of 106, based on positive RT-PCR
results on lysed cells and cell culture supernatant harvest-
ed 54 h after inoculation.
Animal Inoculation
Neither clinical disease nor gross pathologic changes
were observed in chickens or pigs. Repeated attempts to
isolate SARS-CoV from swabs, blood, and organs on Vero
V76 had negative results. No significant (drop in titer
within 1 log) impact of tissue processing on the infectivity
of virus during virus isolation was observed by using lung
tissues from one control chicken and one pig under control
conditions. The tissue was spiked with SARS-CoV before
homogenization, and virus recovery was compared to the
correspondingly diluted inoculum on Vero E6 and Vero
V76 cells (Table 1). Additional attempts at virus isolation
were carried out on PT-K75 cells and, with chicken sam-
ples, on chicken embryo kidney epithelial cells. The results
were again negative, as confirmed by RT-PCR on the inoc-
ulated cells.
RT-PCR assays were undertaken by using three sets of
primers, one developed at the National Microbiology
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Table 1. Relative sensitivity of virus isolation and RT-PCR in tissue samples spiked with the SARS virus before homogenization
a,b 
Virus isolation (PFU/100 µL)  RT-PCR (100 µL) 
Tissue samples  Vero E6  Vero V76  NML primers  N primers  BNI primers 
Virus control  -5.8  -6  -8  -10  -10 
Chicken lung   -5.6  -5.75  -7  -9  -9 
Pig lung   -5.5  -5.7  -7  -9  -9 
aRT-PCR, reverse transcriptase–polymerase chain reaction; SARS, severe acute respiratory syndrome; N, nucleocapsid. 
bThe highest dilution in which the virus or the RNA were detected is given in log10
. Laboratory during the investigation of the Toronto out-
break of SARS, which targeted the polymerase gene, a sec-
ond (BNI) set also within the polymerase gene, and the
third set targeting the nucleocapsid gene region. Due to the
presence of 3′-coterminal nested mRNAs and genomic
RNA (6,7) during coronavirus replication, nucleocapsid
RT-PCR was expected to be more sensitive in samples
containing replicating virus. The originally used NML
primers were less sensitive than the other two sets of
primers (BNI pol and N), and the samples were retested
with these two sets of primers. Sensitivity of the RT-PCR
employing the individual primer sets is illustrated in Table
1, as determined by using negative control lung tissues
spiked with SARS-CoV. RT-PCR with the N and the BNI
primers detected viral RNA equivalent to approximately
10-3/-4 PFU.
RT-PCR amplicons were detected in blood samples
from chickens and pigs at 2 (pig 9, chickens 114 and 115)
and 3 (pigs 10, 11, 12, chickens 116, 117, 118) dpi using
the NMLpolymerase primers. Positive results using a two-
step RT-PCR assay, aimed at detecting negative strands of
viral RNA, indicated that replicating virus was present in
the above positive pig and chicken blood samples (Figure).
By using N primers and the BNI primers, viral RNA was
detected in blood of all inoculated chickens up to 7 dpi and
in chicken 113 at 15 dpi (Table 2). 
No viral amplicons were generated from any of the har-
vested organs or swabs when the NMLpolymerase primers
were used; however, the N primers yielded amplicons from
spleens of two pigs at days 7 and 13 after inoculation, and
in a number of chicken organs. Lung, kidney, and trachea
were positive in some birds at 13 to 16 dpi, while liver,
spleen, and jejunum samples were all negative. These
results were confirmed with BNI polymerase primers
(Table 3). Sequence analysis of selected amplicons con-
firmed the SARS-CoV nucleotide sequence. 
No SARS-CoV–neutralizing antibodies (90% reduction
of virus plaques on Vero E6 cells) were detected in pre-
bleedings from pigs and chickens. The preexisting anti-
bodies against PRCV/TGEV in pigs did not neutralize
SARS-CoV and decreased during the experiment.
Neutralizing antibody against SARS-CoV developed in
pigs, with titers ranging from 1:10 to 1:160 at the time of
euthanasia. The SARS antibody titers corresponded for
both types of virus neutralization tests (the macrotiter
plaque reduction assay and the microtiter CPE blocking
assay). Table 4 summarizes the changes in SARS- and
TGEV-neutralizing antibodies in pigs during the course of
the experiment. No antibodies >1:10 were detected in
chicken serum samples on the final bleed.
Discussion
After the experimental exposure of chickens and pigs to
SARS-CoV, we detected coronavirus RNA in blood and
several tissues from both species starting at 2 days after
inoculation. Clearance of low or nonreplicating intra-
venous inoculum from blood, including the viral RNA,
occurs rapidly in a number of viruses (8,9). In light of the
typical clearance rates and the estimated initial virus load
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Figure. Amplification of severe acute respiratory syndrome–asso-
ciated coronavirus (SARS-CoV) RNA in chicken blood, using one-
step and two-step reverse transcriptase–polymerase chain reac-
tion (RT-PCR) with nucleocapsid primers. Lane 1: 100-bp ladder,
the bright band representing 600 bp; Lane 2: chicken 115, 2 days
postinocuation (dpi), one-step RT-PCR; lane 3: chicken 115, 2 dpi,
two-step RT-PCR (detecting negative-strand RNA); lane 4: chick-
en 117, 3 dpi, one-step RT-PCR; lane 5: chicken 117, 3 dpi, two-
step RT-PCR; lane 6: chicken 115, 4 dpi, one-step RT-PCR; lane
7: chicken 115, 4 dpi, two-step RT-PCR; lane 8: SARS-CoV–infect-
ed cells; lane 9: negative control.
Table 2. RT-PCR on blood samples from chickens using different 
primer sets
a 
Primers 
dpi  Chicken no.  NML pol  N  BNI pol 
2  113  -  +  + 
  114  +  +  + 
  115  +  +  + 
3  116  +  +  + 
  117  +  +  + 
  118  +  +  + 
4  113  -  +  + 
  114  -  -  + 
  115  -  +  + 
5  116  -  +  + 
  117  -  +  + 
  118  -  -  - 
6  113  -  +  + 
  114  -  +  + 
  115  -  +  + 
7  116  -  +  + 
  117  -  -  - 
  118  -  -  - 
13  114  -  -  - 
14  116  -  -  - 
15  113  -  +  + 
16  117  -  -  - 
aRT-PCR, reverse transcriptase–polymerase chain reaction; dpi, days postinfection; 
pol, polymerase; N, nucleocapsid. of 5 PFU/100 µL (porcine blood), the detection of RNA,
corresponding to a minimum of 10-3 PFU/ 100 µL, in
blood at 48 h after inoculation is likely not due to a non-
replicating residual virus inoculum. Our data suggest that
pigs and chickens of the age used in the experiment were
infected with SARS-CoV and, to a very limited degree,
supported virus replication. The unsuccessful attempts at
virus isolation could be explained by a very low rate of
virus replication perhaps combined with loss of infectivity
during the sample collection and processing. Although the
observed decrease in virus recovery (virus spiked control
samples) is not significant, it may have played a role in
case of the low virus load. The intravenous route likely
does not represent the route of infection in a field situation,
and the question of possible natural infection of chickens
and pigs with SARS-CoV remains open. 
Neutralizing antibodies against SARS-CoV developed
in the pigs within 2 weeks of inoculation. These antibodies
did not cross-react with TGEV/PRCV in a TGEV neutral-
ization assay (PRCV and TGEV are indistinguishable in
the virus neutralization assays) (10). Likewise, the
preinoculation serum samples with the highest TGEV-neu-
tralizing antibodies did not neutralize SARS-CoV, and the
neutralizing antibodies against TGEV decreased as the
SARS antibody titers increased. Based on the serum neu-
tralization tests, TGEV/PRCV and SARS-CoV do not
appear to be antigenically closely related, an observation
supported by the initial genomic analysis (1,2). The cross-
neutralization with TGEV/PRCV was initially a concern
after the publication of immunohistochemical assays on
SARS-CoV–infected cells (11). Since virus-neutralizing
antibodies often take approximately 3 weeks to develop in
chickens, no conclusions were made with regard to the low
or absent antibody titers in their sera at 2 weeks after inoc-
ulation. In conclusion, the limited extent of virus replica-
tion as indicated by RT-PCR, the failure to isolate the
virus, and the lack of virus shedding indicate that neither
pigs nor chickens are likely to play a role as an amplifying
host.
Acknowledgments
We thank Gopi Nayar for the results of a competitive
enzyme-linked immunosorbent assay for porcine respiratory
coronavirus/transmissible gastroenteritis virus; June Larence for
the preparation of the primary chicken embryo epithelial kidney
cells; and Harvey Artsob for the critical review of the manuscript.
Dr. Weingartl is head of the Canadian Food Inspection
Agency’s Special Pathogens Unit at the Canadian Science Centre
for Human and Animal Health. Her research interests are emerg-
ing and zoonotic viruses of veterinary importance.
References
1. Marra MA, Jones SJM, Astell CR, Holt RA, Brooks-Wilson A,
Butterfield YSN, et al. The genome sequence of the SARS-
associated–CoV. Science 2003;300:1399–404. 
2. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle
JP, et al. Characterization of a novel coronavirus associated with
severe acute respiratory syndrome. Science 2003;300:1394–9.
3. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van
Amerongen G, van Riel D, et al. Newly discovered coronavirus as the
primary cause of severe acute respiratory syndrome. Lancet
2003;362:263–70.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 2, February 2004 183
RESEARCH SARS ORIGINS
Table 3. Summary of RT-PCR results on chicken tissues
a 
Lung  Trachea  Heart  Liver  Spleen  Kidney  Jejunum 
Chicken no.  dpi  N  BNI  N  BNI  N  BNI  N  BNI  N  BNI  N  BNI  N  BNI 
115  6  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
118  7  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
114  13  +  +  +  +  -  -  -  -  -  -  +  -  -  - 
116  14  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
113  15  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
117  16  +  -  +  -  -  -  -  -  -  -  +  +  -  - 
aRT-PCR, reverse transcriptase–polymerase chain reaction; dpi, days postinfection; N, nucleocapsid. 
Table 4. Overview of virus neutralization titers for pig preimmune and immune sera against SARS-CoV and TGEV
a 
Pre-inoculation bleed serum antibody titer  Final bleed serum antibody titer 
Pig no.  VNT TGEV  VNT SARS  PRNT SARS  VNT TGEV  VNT SARS  PRNT SARS 
7  0  0  0  0  20  10 
8  20+  0  0  20  320  160 
9  10  0  0  0  160  80 
10  20  0  0  10  80+  80 
11  10  0  0  0  40  40 
12  20  0  0  0  80  80 
aDetermined by microtiter virus neutralization test (VNT) and plaque reduction neutralization test (PRNT). SARS-CoV, severe acute respiratory syndrome-coronavirus; 
TGEV, transmissible gastroenteritis virus. 4. Cox E, Pensaert M, Hooyberghs J, Van Deun K. Sites of replication
of porcine respiratory coronavirus in 5-week-old pigs with or without
maternal antibodies. Adv Exp Med Biol 1990;276:429–33.
5. Beaty BJ, Calisher CH, Shope RS. Arboviruses. In: Schmidt NJ,
Emmons RW, editors. Diagnostic procedures for viral, rickettsial and
chlamydial infections. 6th ed. Washington: American Public Health
Association; 1989. p. 797–856.
6. Lai MMC, Cavanagh D. The molecular biology of coronaviruses.
Adv Virus Res 1997;48:1–100.
7. Sawicki SG, Sawicki DL. Anew model for coronavirus transcription.
Adv Exp Med Biol 1998;440:215–9.
8. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin
MA, et al. Human immunodeficiency virus type 1 neutralizing anti-
bodies accelerate clearance of cell-free virions from blood plasma.
Nat Med 1999;5:211–6.
9. Bernard KA, Klimstra WB, Johnston RE. Mutations of the E2 glyco-
protein of Venezuelan equine encephalitis virus confer heparan sul-
fate interaction, low morbidity, and rapid clearance from blood of
mice. Virology 2000;276:93–103.
10. Have P. Infection with a new porcine respiratory coronavirus in
Denmark: serologic differentiation from transmissible gastroenteritis
virus using monoclonal antibodies. Adv Exp Med Biol
1990;276:435–9.
11. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et
al. A novel coronavirus associated with severe acute respiratory syn-
drome. N Engl J Med 2003;348:1953–66
Address for correspondence: Hana M. Weingartl, NCFAD, CFIA, 1015
Arlington St., Winnipeg, MB, R3E 3M4, Canada; fax: 204-789-2038;
email: hweingartl@inspection.gc.ca 
184 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 2, February 2004
EMERGENCE OF SARS
Search   past   issues   of   EID   at   www.cdc.gov/eid